A systematic review on effectiveness and safety of eliglustat for type 1 Gaucher disease

Bibliography

• Brady RO, Kanfer JN, Shapiro D. Metabolism of glucocerebrosides.II. Evidence of an enzymatic deficiency in Gaucher disease. Biochem Biophys Res Commun 1965;18:221-5
   PubMed Web of Science ®Google Scholar
• Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for gaucher's disease. N Engl J Med 1991;324:1464-70
   PubMed Web of Science ®Google Scholar
• Barton NW, Furbish FS, Murray GJ, et al. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with gaucher disease. Proc Natl Acad Sci USA 1990;87:1913-16
   PubMed Web of Science ®Google Scholar
• Beutler E, Kay A, Saven A, et al. Enzyme replacement therapy for gaucher disease. Blood 1991;78:1183-9
   PubMed Web of Science ®Google Scholar
• Grabowski GA, Barton NW, Pastores G, et al. Enzyme therapy in type 1 gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995;122:33-9
   PubMed Web of Science ®Google Scholar
• Gonzalez DE, Turkia HB, Lukina EA, et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: results from a randomized, double-blind, multinational, phase 3 study. Am J Hematol 2013;88:166-71
   PubMed Web of Science ®Google Scholar
• Zimran A, Altarescu G, Phillips M, et al. Phase I/II and extension study of velaglucerase alfa replacement therapy in adults with type 1 gaucher disease: 48-month experience. Blood 2010;115:4651-46
   PubMed Web of Science ®Google Scholar
• Zimran A, Brill-Almon E, Chertkoff R, et al. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for gaucher disease. Blood 2011;118:5767-73
   PubMed Web of Science ®Google Scholar
• de Fost M, van Noesel CJ, Aerts JM, et al. Persistent bone disease in adult type 1 gaucher disease despite increasing doses of enzyme replacement therapy. Haematologica 2008;93:1119-20
   PubMed Web of Science ®Google Scholar
• Radin NS. Treatment of Gaucher disease with an enzyme inhibitor. Glycoconj J 1996;13:153-7
   PubMed Web of Science ®Google Scholar
• Smid BE, Aerts JMFG, Boot RG, et al. Pharmacological small molecules for the treatment of lysosomal storage disorders. Expert Opin Investig Drugs 2010;19:1367-79
   PubMed Web of Science ®Google Scholar
• Cox TM, Aerts JM, Andria G, et al. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) gaucher disease: a position statement. J Inherit Metab Dis 2003;26:513-26
   PubMed Web of Science ®Google Scholar
• Cox T, Lachmann R, Hollak C, et al. Novel oral treatment of gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000;355:1481-5
   PubMed Web of Science ®Google Scholar
• Cox TM, Amato D, Hollak CE, et al. Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 gaucher disease: a prospective, open-label non-inferiority study. Orphanet J Rare Dis 2012;7:102
   Google Scholar
• McEachern KA, Fung J, Komarnitsky S, et al. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of gaucher disease. Mol Genet Metab 2007;91:259-67
   PubMed Web of Science ®Google Scholar
• Platt FM, Reinkensmeier G, Dwek RA, Butters TD. Extensive glycosphingolipid depletion in the liver and lymphoid organs of mice treated with N-butyldeoxynojirimycin. J Biol Chem 1997;272:19365-72
   PubMed Web of Science ®Google Scholar
• Lee L, Abe A, Shayman JA. Improved inhibitors of glucosylceramide synthase. J Biol Chem 1999;274:14662-9
   PubMed Web of Science ®Google Scholar
• Shayman JA. Eliglustat tartrate: glucosylceramide synthase inhibitor treatment of type 1 gaucher disease. Drugs Future 2010;35:613-20
   PubMed Web of Science ®Google Scholar
• Shayman JA. The design and clinical development of inhibitors of glycosphingolipid synthesis: will invention be the mother of necessity? Trans Am Clin Climatol Assoc 2013;124:46-60
   Google Scholar
• Abe A, Gregory S, Lee L, et al. Reduction of globotriaosylceramide in fabry disease mice by substrate deprivation. J Clin Invest 2000;105:1563-71
   PubMed Web of Science ®Google Scholar
• Larsen SD, Wilson MW, Abe A, et al. Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain. J Lipid Res 2012;53:282-91
   PubMed Web of Science ®Google Scholar
• Peterschmitt MJ, Burke A, Blankstein L, et al. Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers. J Clin Pharmacol 2011;51:695-705
   PubMed Web of Science ®Google Scholar
• Lukina E, Watman N, Arreguin EA, et al. A Phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood 2010;116(6):893-9
   PubMed Web of Science ®Google Scholar
• Lukina E, Watman N, Arreguin EA, et al. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood 2010;116:4095-8
   PubMed Web of Science ®Google Scholar
• Peterschmitt MJ, Lukina E, Watman N, et al. Eliglustat, an investigational oral therapy for gaucher disease type 1: phase 2 results after 4 years of treatment. Blood. Conference: 54th Annual Meeting of the American Society of Hematology, ASH; 2012
   Google Scholar
• Peterschmitt MJ, Lukina EA, Watman N, et al. Eliglustat, an investigational oral therapy for Gaucher disease type 1: phase 2 results after 3 years. 53rd Annual meeting of the American Society of Hematology, ASH; 2011
   Google Scholar
• Peterschmitt MJ, Kamath RS, Lukina E, et al. Improvements in skeletal manifestations in Gaucher disease type 1 patients after 3 years of treatment with oral eliglustat during a phase 2 trial. 53rd Annual Meeting of the American Society of Hematology, ASH; 2011
   Google Scholar
• Puga AC, Lukina E, Watman N, et al. Biomarker responses after 3 years of treatment with eliglustat, an investigational oral therapy for gaucher disease type 1 (GD1). Annual symposium of the Society for the Study of Inborn Errors of Metabolism; 2011
   Google Scholar
• Available from: www.clinicaltrials.gov [Last accessed 12 June 2010]
   Google Scholar
• Available from: http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=875
   Google Scholar
• Packman S, Amato D, Dasouki M, et al. ENGAGE: A phase 3, randomized, double-blind, placebo-controlled, multi-center study to investigate the efficacy and safety of eliglustat in adults with gaucher disease type 1 (GD1): 9 month results. ASHG; 2013. Available from: http://abstracts.ashg.org/cgi-bin/2013/ashg13s.pl?author=packman&sort=ptimes&sbutton=Detail&absno=130122683&sid=571755
   Google Scholar
• Available from: http://news.genzyme.com/press-release/genzyme-announces-positive-new-data-two-phase-3-studies-oral-eliglustat-tartrate-gauch [Last accessed 18 November 2013]
   Google Scholar
• Hollak CEM. Short-term withdrawal from imiglucerase: what can we learn from it? Blood Cells Mol Dis 2011;46:105-6
   Google Scholar
• Zimran A, Altarescu G, Elstein D. Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supply. Blood Cells Mol Dis 2011;46:111-14
   Google Scholar
• Goldblatt J, Fletcher JM, McGill J, et al. Enzyme replacement therapy “drug holiday”: results from an unexpected shortage of an orphan drug supply in australia. Blood Cells Mol Dis 2011;46:107-10
   PubMed Web of Science ®Google Scholar
• Balwani M, Cox TM, Drelichman G, et al. ENCORE: a randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in gaucher disease type 1 patients on enzyme replacement therapy who have reached therapeutic goals. American Society of Human Genetics; 2013. Available from: http://www.ashg.org/2013meeting/abstracts/fulltext/f130122761.htm
   Google Scholar
• Cox TM, Drelichman G, Cravo R, et al. ENCORE: A randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in gaucher disease type 1 patients on enzyme replacement therapy who have reached therapeutic goals. Abstract of WORLDsymposium 2014. Mol Genet Metab 2014;111:S1-S118
   Google Scholar
• Arends M, van DL, Biegstraaten M, Hollak CE. Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature. Br J Haematol 2013;161:832-42
   PubMed Web of Science ®Google Scholar
• Langeveld M, Ghauharali KJ, Sauerwein HP, et al. Type I gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance. J Clin Endocrinol Metab 2008;93:845-51
   PubMedGoogle Scholar
• Neudorfer O, Giladi N, Elstein D, et al. Occurrence of parkinson's syndrome in type I gaucher disease. QJM 1996;89:691-4
   PubMed Web of Science ®Google Scholar
• Pavlova EV, Wang SZ, Archer J, et al. B cell lymphoma and myeloma in murine Gaucher's disease. J Pathol 2013;231:88-97
   PubMed Web of Science ®Google Scholar
• Hollak CE, Aerts JM, Ayme S, Manuel J. Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders. Orphanet J Rare Dis 2011;6:16
   PubMed Web of Science ®Google Scholar
• van Dussen L, Biegstraaten M, Dijkgraaf MGW, Hollak CE. Modelling gaucher disease progression: long term enzyme replacement therapy reduces the incidence of splenectomy and bone complications. Thesis Univeristy of Amsterdam: Two decades of treatment for gaucher disease. Amsterdam; 2014
   Google Scholar
• Biegstraaten M, Mengel E, Marodi L, et al. Peripheral neuropathy in adult type 1 gaucher disease: a 2-year prospective observational study. Brain 2010;133:2909-19
   PubMedGoogle Scholar
• Hollak CE, Hughes D, van Schaik IN, et al. Miglustat (Zavesca) in type 1 gaucher disease: 5-year results of a post-authorisation safety surveillance programme. Pharmacoepidemiol Drug Saf 2009;18:770-7
   PubMed Web of Science ®Google Scholar
• Ross L, Peterschmitt J, Puga AC, et al. Eliglustat safety profile based on a pooled analysis of data from four trials in gaucher disease type I. Abstract of WORLDsymposium 2014. Mol Genet Metab 2014;111:S1-S118
   Google Scholar